Black Diamond Therapeutics (BDTX) disclosed plans Monday to restructure business to focus on advancing its BDTX-1535 lead program candidate and extending its financial resources into Q2 2026.
Black Diamond said it expects to report initial results from phase 2 testing of BDTX-1535, a treatment for a form of recurrent non-small cell lung cancer characterized by epidermal growth factor receptor mutations, early in 2025.
The company also said chief business and financial officer Fang Ni is leaving the company as part of the restructuring, while Erika Jones, currently senior vice president of finance and principal accounting officer, was named principal financial officer.
Chief People Officer Elizabeth Montgomery is also leaving the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。